ClinicalTrials.gg

Program

Folfox protocol

Also written as “sunitinib + FOLFOX”, “FOLFOX” and “FOLFOX regimen”.

Its studies are mostly in Colorectal Neoplasms · Cholangiocarcinoma · Stomach Neoplasms · Neoplasms, led by 11 companies.

Furthest: phase 3, since Feb 23, 200915 company-led studies, 6 open or runningNext primary completion: Apr 16, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche31 open or runningphase 1since Feb 23, 2009Feb 23, 2009Aug 31, 2030phase 1 · NCT04929223
AstraZeneca21 open or runningphase 3since Nov 13, 2006Nov 13, 2006Nov 30, 2027phase 2 · NCT05702229
Pfizer20 open or runningphase 2since Feb 1, 2008Jan 11, 2008none ahead
Alethia Biotherapeutics11 open or runningphase 2since Nov 17, 2023Nov 17, 2023none ahead
Amgen10 open or runningphase 2since Mar 20, 2009Mar 20, 2009none ahead
Bristol-Myers Squibb10 open or runningphase 1since May 24, 2007May 24, 2007none ahead
Cardiff Oncology11 open or runningphase 2since Oct 24, 2023Oct 24, 2023Apr 16, 2027phase 2 · NCT06106308
Fosun Pharma11 open or runningphase 2since Apr 2, 2025Apr 2, 2025Apr 30, 2028phase 2 · NCT06936527
Genmab11 open or runningphase 2since Apr 4, 2018Apr 4, 2018May 2028phase 2 · NCT03526835
Lisata Therapeutics10 open or runningphase 2since Jan 26, 2023Jan 26, 2023none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 2since Oct 22, 2008Oct 22, 2008none ahead

Also a collaborator on its studies: merck-pte-ltd-singapore.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Nov 13, 2006.

  1. May 24, 2007Bristol-Myers Squibb's first study: phase 1 study in NeoplasmsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00479583 · 25 enrolled · United States, France
  2. Jan 11, 2008Pfizer's first study: phase 1 study in Colorectal NeoplasmsNew to PfizerPfizer · NCT00599924 · 53 enrolled · United States
  3. Feb 1, 2008Phase 2 study in Colorectal NeoplasmsPfizer · NCT00615056 · 171 enrolled · United States, Canada, France and more
  4. Oct 22, 2008Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Colorectal NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00778830 · 289 enrolled · Singapore
  5. Feb 23, 2009Hoffmann-La Roche's first study: phase 1 study in Colorectal NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT00851136 · 9 enrolled
  6. Mar 5, 2009Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT00873756 · 23 enrolled · United States
  7. Mar 20, 2009Amgen's first study: phase 2 study in Colorectal NeoplasmsNew to AmgenAmgen · NCT00866944 · 35 enrolled · France, Germany
  8. Apr 4, 2018Genmab's first study: phase 2 study in Colorectal NeoplasmsNew to GenmabGenmab · NCT03526835 · 560 planned · United States, Belgium, France and more
  9. Jun 11, 2021Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT04929223 · 542 planned · United States, Australia, Canada and more
  10. Dec 7, 2022Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229 · 163 planned · United States, China, Japan and more
  11. Jan 26, 2023Lisata Therapeutics's first study: phase 2 study in CholangiocarcinomaNew to Lisata TherapeuticsLisata Therapeutics · NCT05712356 · 66 enrolled · United States
  12. Oct 24, 2023Cardiff Oncology's first study: phase 2 study in Colorectal NeoplasmsNew to Cardiff OncologyCardiff Oncology · NCT06106308 · 110 enrolled · United States
  13. Nov 17, 2023Alethia Biotherapeutics's first study: phase 2 study in Colorectal NeoplasmsNew to Alethia BiotherapeuticsAlethia Biotherapeutics · NCT06225843 · 17 planned · Canada
  14. Apr 2, 2025Fosun Pharma's first study: phase 2 study in Colorectal NeoplasmsNew to Fosun PharmaFosun Pharma · NCT06936527 · 102 planned · China

Ahead

  1. Apr 16, 2027Primary completion: phase 2 study in Colorectal NeoplasmsCardiff Oncology · NCT06106308
  2. Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229
  3. Apr 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsFosun Pharma · NCT06936527
  4. May 2028Primary completion: phase 2 study in Colorectal NeoplasmsGenmab · NCT03526835

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06936527Colorectal Neoplasms · China2By invitationFosun PharmaApr 30, 2028102
NCT06225843Colorectal Neoplasms · Canada2RecruitingAlethia BiotherapeuticsMar 202617
NCT06106308Colorectal Neoplasms · United States2Active, not recruitingCardiff OncologyApr 16, 2027110
NCT05712356Cholangiocarcinoma · United States2CompletedLisata TherapeuticsApr 5, 202666
NCT05702229Stomach Neoplasms · United States, China, Japan and more2RecruitingAstraZenecaNov 30, 2027163
NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more1RecruitingHoffmann-La RocheAug 31, 2030542
NCT03526835Colorectal Neoplasms · United States, Belgium, France and more2RecruitingGenmabMay 2028560
NCT00866944Colorectal Neoplasms · France, Germany2CompletedAmgenJul 201135
NCT00873756Colorectal Neoplasms · United States1CompletedHoffmann-La RocheMar 201423
NCT00851136Colorectal Neoplasms1CompletedHoffmann-La RocheJun 20109
NCT00778830Colorectal Neoplasms · Singapore2CompletedMerck KGaA, Darmstadt, GermanyApr 2014289
NCT00615056Colorectal Neoplasms · United States, Canada, France and more2CompletedPfizerMar 2011171
NCT00599924Colorectal Neoplasms · United States1CompletedPfizerNov 200853
NCT00479583Neoplasms · United States, France1CompletedBristol-Myers SquibbApr 201025
NCT00399035Colorectal Neoplasms · Argentina, Australia, Brazil and more3CompletedAstraZenecaMar 20101,254

How it is read

Names in the registry

  • “sunitinib + FOLFOX”, 7 entries
  • “FOLFOX”, 6 entries
  • “FOLFOX regimen”, 2 entries
  • “FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])”, 2 entries
  • “MCLA-158 + FOLFOX”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.